Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on Cilobradine PK
NCT02264041Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2004
- Primary completion
- Apr 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of cilobradine in angina pectoris and heart failure (HF) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 56 hours and Maximum measured concentration of the analyte in plasma up to 56 hours. Started Jan 2004; status: completed.
02
Drugs
cilobradine
03
Conditions
angina pectorisheart failure (HF)
Beyond the preview
Go deeper on NCT02264041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264041.